tiprankstipranks
Blurbs

Analysts Are Bullish on Top Healthcare Stocks: CTI BioPharma (CTIC), Oncternal Therapeutics (ONCT)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CTI BioPharma (CTICResearch Report), Oncternal Therapeutics (ONCTResearch Report) and Minerva Neurosciences (NERVResearch Report) with bullish sentiments.

CTI BioPharma (CTIC)

BTIG analyst Robert Hazlett maintained a Buy rating on CTI BioPharma yesterday and set a price target of $10.00. The company’s shares closed last Wednesday at $4.68, close to its 52-week high of $5.25.

According to TipRanks.com, Hazlett is a 3-star analyst with an average return of 2.5% and a 36.9% success rate. Hazlett covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Eiger Biopharmaceuticals, and Paratek Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for CTI BioPharma with a $8.08 average price target, representing a 74.9% upside. In a report issued on April 4, JMP Securities also reiterated a Buy rating on the stock with a $5.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Oncternal Therapeutics (ONCT)

In a report released yesterday, Kaveri Pohlman from BTIG maintained a Buy rating on Oncternal Therapeutics, with a price target of $5.00. The company’s shares closed last Wednesday at $1.15, equals to its 52-week low of $1.15.

According to TipRanks.com, Pohlman ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -30.8% and a 19.0% success rate. Pohlman covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Checkmate Pharmaceuticals, and Mersana Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Oncternal Therapeutics with a $5.00 average price target.

Minerva Neurosciences (NERV)

In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Minerva Neurosciences, with a price target of $6.00. The company’s shares closed last Wednesday at $0.76, close to its 52-week low of $0.63.

According to TipRanks.com, Shrader is a 1-star analyst with an average return of -1.0% and a 32.2% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Aldeyra Therapeutics, Sigilon Therapeutics, and Pliant Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Minerva Neurosciences with a $6.67 average price target, which is an 852.9% upside from current levels. In a report issued on April 8, H.C. Wainwright also maintained a Buy rating on the stock with a $5.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CTIC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed